The Bull Case for Amprius Technologies Just Got Stronger

Key Points

• Amprius Technologies received a $75 million Department of War grant to expand battery manufacturing for military drones, strengthening its bull case significantly.
• Analysts, including Oppenheimer's Colin Rusch, reaffirmed bullish sentiment with a Moderate Buy rating and a $22.09 price target after the grant announcement.
• Execution risk remains the biggest challenge, as Amprius must scale South Korean contract manufacturing without owning the new production facility itself.

Amprius Technologies NYSE: AMPX just received a new $75 million Department of War (DoW) grant that completely changes the narrative and strengthens the bull case. In short, the money shifts the company from a high-risk speculation with interesting technology to a primary, in-demand supplier for government needs, with an accelerated timeline to profitability.

Mitigated risks include dilution, Chinese/international manufacturing, and questionable demand. Questions answered include how the company will secure contracts, whether it can achieve full compliance with the National Defense Authorization Act (NDAA), and how it will make money. For the market, this means a shift in perspective: investors will judge the company on milestones and execution rather than potential alone.

Amprius Technologies: Critical to the Drone Industry

Amprius Technologies is in demand for its batteries, which provide superior energy density, discharge, and recharge rates while improving range and payload capacity for vehicles they power. The grant, issued by the DoW Industrial Base Analysis and Sustainment Program, will help Amprius expand its manufacturing capacity. The company aims to retrofit an EV battery facility, in partnership with its South Korean manufacturing base, to manufacture batteries for Group 1-3 unmanned systems.

Group 1-3 unmanned systems include small, tactical drones weighing less than 20 pounds, as well as larger unmanned aircraft like Textron’s NYSE: TXT RQ-7B Shadow and Boeing’s NYSE: BA Integrator. With drones and unmanned systems now a focus for global military powers, Amprius is well-positioned to serve as a provider for the United States and its partners.

Analysts' responses to the news highlight a shifting narrative, with initial reactions reaffirming bullish sentiment and price targets, aligning with the trend. Colin Rusch of Oppenheimer says the news addresses a key concern about Amprius by allowing it to expand production capacity with relatively little of its own capital, while also highlighting the military’s urgent demand for advanced batteries. What this means for investors is strengthened conviction in the consensus sentiment and price targets, which are pegged at Moderate Buy and $22.09, more than 130% upside from the critical support target.

The Bottom Is In for Amprius Technologies

Amprius Technologies still has risks, but a lower stock price is near the bottom of the list. While short interest was high as of mid-September, the grant news will likely trigger short covering and unleash the institutional market.

Institutions have been hesitant to invest in AMPX to date, but can now focus more attention on it because the outlook has been significantly de-risked, including solvency, capital structure, valuation, and outlook. The likely outcome is that inflows begin soon, ramping over time as the company reports quarterly earnings and hits its milestones. Even so, with nearly 500 institutions owning at least some shares as of late September, it won’t take much for this group to impact price action.

Amprius's critical support target is near $9, coincident with the 150-week EMA, a proxy for buy-and-hold investors, including institutions. It is unlikely to break, given the latest development, and is likely to produce rallies when touched or crossed. Indicators such as MACD and stochastic reveal a market ready to rebound, with stochastic already showing a strong “Buy” signal low in its range.

Amprius Catalysts Versus Execution Risks

Amprius Technologies' immediate catalyst, aside from the grant, is the upcoming Q3 earnings report. The Q2 release was excellent, including improved guidance and expectations that hypergrowth will continue. AMPX is likely to outperform while providing more clarity on its next phase, strengthening market sentiment and prompting institutions to act. The report is due in early November; analysts forecast revenue to grow by nearly 70%, with the inflection to profitability expected over the next two to three quarters.

Upcoming catalysts include several grant-related milestones. The deal is structured to reimburse the company for its investments, starting with retrofitting and retooling the existing line. After that, securing partner and in-kind contributions, NDAA compliance certification, operational start-up, and product ramp will unlock additional funding. Long-term, the deal aims to produce 12 million cells annually, with effective capacity across the target markets.

The biggest risk now is execution. While Amprius has proven it can deliver in small batches, scaling its South Korean contract manufacturing footprint will be challenging, and delays or missteps will be reflected in the stock’s price. The grant doesn’t mitigate the risk, as Amprius will not own the new facility; one of its contract partners will. With this in play, short covering may begin, but that doesn’t mean shorts will exit; most likely, they will simply reposition at higher levels until AMPX hits its milestones.